Actinium Pharmaceuticals, Inc. (FRA:7AY1)

Germany flag Germany · Delayed Price · Currency is EUR
1.231
+0.011 (0.90%)
At close: Nov 28, 2025
-7.09%
Market Cap37.13M
Revenue (ttm)76.71K
Net Income (ttm)-29.49M
Shares Outn/a
EPS (ttm)-0.95
PE Ration/a
Forward PE11.14
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volume81
Open1.231
Previous Close1.220
Day's Range1.231 - 1.231
52-Week Range0.998 - 1.821
Betan/a
RSI54.17
Earnings DateNov 21, 2025

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company advances two clinical stage product candidates, Actimab-A, to treat patients with myeloid malignancies including acute myeloid leukemia and myelodysplastic syndromes; and Iomab-ACT, to improve patient access to and outcomes with cellular therapies, such as CAR-T for various blood cancer indications and gene therapies for non-malignant hematologic ... [Read more]

Industry Biological Products, Except Diagnostic Substances
CEO Sandesh Seth
Employees 37
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 7AY1
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

There is no news available yet.